A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.
221362
Phase 1 other active
Quick answer
A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease. for Kidney Disease is a Phase 1 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Kidney Disease
- Phase
- Phase 1
- Modality
- other
- Status
- active